In this free webinar, learn how new data unveiled at the European Society for Medical Oncology (ESMO) 2024 annual meeting may impact the future of cancer treatment. Attendees will review the status of current antibody-drug conjugates (ADCs) in oncology and how to get the next generation of ADCs into first-in-human trials. The featured speakers will discuss the latest information on the constantly evolving field of theranostics and its promise to significantly improve treatment outcomes.
TORONTO, Sept. 18, 2024 /PRNewswire-PRWeb/ -- It is an exciting time for oncology drug development, characterized by rapid innovation and significant advancements in personalized medicine, and the landscape is witnessing a surge in clinical trials exploring novel mechanisms of action, biomarkers and combination therapies to overcome resistance and enhance efficacy.
What treatment modalities are healthcare providers (HCPs) most excited about? What groundbreaking research is piquing their interest? Are antibody-drug conjugates (ADCs) and theranostics — potentially transformative therapies getting the spotlight of late — living up to their hype?
These questions and more will be answered through a survey of HCPs attending the European Society for Medical Oncology (ESMO) annual meeting — one of the premier events in the oncology community, bringing together thousands of oncologists, researchers and healthcare professionals from around the world to share the latest scientific developments, research findings and clinical advancements in cancer treatment.
Join an engaging webinar that will unveil insights from oncologists surveyed at the ESMO 2024 conference. The expert speakers will identify and explore the data that oncologists consider most impactful from the conference and provide a closer look at the transformative potential of ADCs and theranostics. They will also examine the oncology drug development landscape, highlighting the surge in innovative trials and the strategic shifts in treatment approaches.
Register for this webinar to understand what treatment modalities and research are capturing the attention of oncologists and healthcare professionals in oncology drug development.
Join experts from Syneos Health, Dr. Wouter Bartholomeus, MD, Executive Medical Director Oncology & Hematology; Dr. Patrick Kelly, MD, Vice President, Medical Management, Oncology & Hematology; and Dr. Prateet Minhas, MD, Managing Director, Consulting, for the live webinar on Friday, October 4, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Transforming Oncology Drug Development: Insights from Healthcare Providers on the Frontlines of Cancer Care.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article